In recent weeks, much has been made of psychedelic drugs’ potential to redefine mental health treatment.
UK-startup Clerkenwell Health is opening Europe’s first ever facility to host commercial psychedelic clinical trials in London.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
On International Women’s Day, Psychedelic Health takes a look at just some of the women who are spearheading the psychedelic renaissance in the UK.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
A new report from the Conservative Drug Policy Reform Group (CDPRG) has shown the majority of MPs in the UK support drug policy reform, and highlights...
The new UK drug strategy is aiming to reduce drug-related crime through the largest ever increase in funding.
Awakn has signed a Memorandum of Understanding (MOU) with the Devon Partnership NHS Trust and the University of Exeter to increase access to psychedelic-assisted therapy for...